Loading …
Never Run Out Of Buyers To Sell To.

Abacus Bioscience is developing a new class of immunotherapy that unleashes the power of a novel CD180 platform technology. Our Antigen-Specific Immune Accelerants (ASIA) are POTENT, SPECIFIC and DURABLE, with broad applications across infectious disease and oncology.
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.